



Liste modèle des médicaments essentiels

Amikacin

Section	Indications
Antituberculosis medicines Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Multi-drug resistant <i>Mycobacterium tuberculosis</i>
Access group antibiotics Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)	Premier choix Neutropenia (high-risk) co-prescrite avec cefotaxime
Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Inflammatory and other diseases of prostate (severe) co-prescrite avec cefotaxime
	Acute pyelonephritis (severe) co-prescrite avec ceftriaxone
	Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone
	Acute pyelonephritis (severe)
	Second choix co-prescrite avec cloxacillin
	Sepsis without septic shock

Amoxicillin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid	Premier choix
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)	Acute malnutrition in infants, children or adolescents (uncomplicated) [children]
Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)	Acute malnutrition in infants, children or adolescents (complicated) [children]
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	Acute pharyngitis
Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)	Chronic obstructive pulmonary disease with acute exacerbation
	Periapical abscess without sinus
	Acute otitis media
	Acute sinusitis
	co-prescrite avec gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	co-prescrite avec gentamicin
	Sepsis without septic shock
	Second choix
	Bacterial meningitis
	Autres indications
	Infectious cystitis
	Bacterial infection of unspecified site

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Premier choix Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Second choix Osteomyelitis or osteitis Acute otitis media Other specified prophylactic measures Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
Antituberculosis medicines Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Autres indications Bacterial infection of unspecified site Multi-drug resistant Mycobacterium tuberculosis

Ampicillin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	Premier choix co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	Second choix Bacterial meningitis
	Autres indications Bacterial infection of unspecified site

Azithromycin

Section	Indications
<p>Watch group antibiotics</p> <p>Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)</p>	<p>Premier choix</p> <ul style="list-style-type: none">Chlamydia trachomatisTyphoid feverYawsParatyphoid feverCholeraCholera [children]Trachoma <p>co-prescrite avec ceftriaxone</p> <ul style="list-style-type: none">Gonococcal infection <p>Second choix</p> <ul style="list-style-type: none">Infectious gastroenteritis or colitis without specification of infectious agent <p>co-prescrite avec cefixime</p> <ul style="list-style-type: none">Gonococcal infection

Aztreonam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection</p>	<ul style="list-style-type: none">Other specified bacterial diseases

Bedaquiline

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 100 mg tablet; 20 mg tablet</p>	<ul style="list-style-type: none">Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection</p>	<p>Premier choix</p> <ul style="list-style-type: none">SyphilisCongenital syphilis [children] <p>Autres indications</p> <ul style="list-style-type: none">Bacterial infection of unspecified site

Benzylpenicillin

Section	Indications
Access group antibiotics	Premier choix Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)	Second choix Bacterial meningitis
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	Autres indications Bacterial infection of unspecified site

Capreomycin

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Cefalexin

Section	Indications
Access group antibiotics	Premier choix Bacterial cellulitis, erysipelas or lymphangitis
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	Second choix Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid: 250 mg (as monohydrate)	
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)	
Oral > Solid > dispersible tablet: 125 mg; 250 mg	Autres indications Bacterial infection of unspecified site

Cefazolin

Section	Indications
<p>Access group antibiotics Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection</p>	<p>Premier choix</p> <ul style="list-style-type: none">Other specified prophylactic measures<ul style="list-style-type: none">co-prescrite avec metronidazole <p>Second choix</p> <ul style="list-style-type: none">Osteomyelitis or osteitisBacterial infection of joint <p>Autres indications</p> <ul style="list-style-type: none">Surgical site infection

Cefepime

Section	Indications
<p>Watch group antibiotics Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection</p>	<p>Other specified bacterial diseases</p>

Cefiderocol

Section	Indications
<p>Reserve group antibiotics Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection</p>	<p>Carbapenem-resistant <i>Pseudomonas aeruginosa</i></p> <p>Carbapenem resistant Enterobacteriales</p>

Cefixime

Section	Indications
<p>Watch group antibiotics Oral > Liquid: 100 mg per 5 mL powder for oral liquid Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)</p>	<p>Second choix</p> <ul style="list-style-type: none">Infectious gastroenteritis or colitis without specification of infectious agent<ul style="list-style-type: none">co-prescrite avec azithromycin <p>Gonococcal infection</p>

Cefotaxime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	Premier choix Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate)
	Second choix Osteomyelitis or osteitis Bacterial infection of joint Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock
	Autres indications Bacterial infection of unspecified site

Ceftaroline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

Ceftazidime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection</p>	<p>Premier choix</p> <p>co-prescrite avec vancomycin</p> <p>Endophthalmitis</p> <p>Autres indications</p> <p>Pseudomonas aeruginosa resistant to other antibiotic</p>

Ceftazidime + avibactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p> <p>Carbapenem resistant Enterobacteriales</p>

Ceftolozane + tazobactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 1 g + 0.5 g powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p>

Ceftriaxone

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p>	<p>Premier choix</p> <p>Typhoid fever</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</p> <p>Paratyphoid fever</p> <p>Other specified pneumonia (Hospital-acquired pneumonia)</p> <p>Bacterial meningitis</p> <p>co-prescrite avec amikacin</p> <p>Acute pyelonephritis (severe)</p> <p>co-prescrite avec amikacin</p> <p>Inflammatory and other diseases of prostate (severe)</p> <p>co-prescrite avec azithromycin</p> <p>Gonococcal infection</p> <p>co-prescrite avec clarithromycin</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe)</p>

co-prescrite avec metronidazole

Necrotising fasciitis

co-prescrite avec metronidazole

Peritonitis (mild-moderate)

co-prescrite avec metronidazole

Peritonitis (severe)

co-prescrite avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrite avec metronidazole

Peritoneal abscess (severe)

co-prescrite avec vancomycin

Endophthalmitis

Second choix

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Autres indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt)
powder for injection; 750 mg in vial (as sodium salt) powder for injection;
1.5 g in vial (as sodium salt) powder for injection

Indications

Second choix

Other specified prophylactic measures

Chloramphenicol

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)</p> <p>Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection</p> <p>Oral > Liquid: 150 mg per 5 mL (as palmitate)</p> <p>Oral > Solid: 250 mg capsule</p>	<p>Second choix</p> <p>Bacterial meningitis</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Ciprofloxacin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 2 mg per mL (as hydrate)</p> <p>Oral > Liquid: 250 mg per 5 mL (anhydrous)</p> <p>Oral > Solid: 250 mg (as hydrochloride)</p> <p>Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)</p> <p>Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)</p>	<p>Premier choix</p> <p>Neutropenia (low-risk)</p> <p>Inflammatory and other diseases of prostate (mild to moderate)</p> <p>Typhoid fever</p> <p>Paratyphoid fever</p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>Acute pyelonephritis (mild to moderate)</p> <p>Second choix</p> <p>Cholera</p> <p>Cholera [children]</p> <p>co-prescrite avec metronidazole</p> <p>Peritoneal abscess (mild-moderate)</p> <p>co-prescrite avec metronidazole</p> <p>Peritonitis (mild-moderate)</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Clarithromycin

Section

Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

Indications

Premier choix

co-prescrite avec cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescrite avec ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

Second choix

Acute pharyngitis

co-prescrite avec amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

Autres indications

Helicobacter pylori associated gastric ulcer

Clindamycin

Section

Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Indications

Premier choix

co-prescrite avec piperacillin + tazobactam

Necrotising fasciitis

Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

Autres indications

Bacterial infection of unspecified site

Clofazimine

Section

Antituberculosis medicines

Oral > Solid: 100 mg; 50 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Antileprosy medicines

Oral > Solid: 100 mg; 50 mg

Leprosy

Cloxacillin

Section	Indications
Access group antibiotics	Premier choix
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid	Bacterial infection of joint
Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule	Osteomyelitis or osteitis
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	Bacterial cellulitis, erysipelas or lymphangitis
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid	Second choix
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection	co-prescrite avec amikacin
Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)	Sepsis without septic shock
	Autres indications
	Bacterial infection of unspecified site

Colistin (injection)

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases
Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)	Carbapenem resistant Acinetobacter baumannii
Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Carbapenem-resistant Pseudomonas aeruginosa
	Carbapenem resistant Enterobacteriales

Cycloserine

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid: 250 mg; 125 mg	

Dapsone

Section	Indications
Antileprosy medicines	Leprosy
Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	

Daptomycin

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases
Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	

Delafloxacin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 300 mg lyophilized powder for injection</p> <p>Oral > Solid: 450 mg</p>	Methicillin resistant <i>Staphylococcus aureus</i>

Delamanid

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid > dispersible tablet: 25 mg</p> <p>Oral > Solid > tablet: 50 mg</p>	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Doxycycline

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)</p> <p>Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)</p> <p>Parenteral > General injections > unspecified: 100 mg in vial powder for injection</p> <p>Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)</p> <p>Oral > Solid > dispersible tablet: 100 mg (as monohydrate)</p> <p>Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)</p> <p>Oral > Solid > dosage form: 100 mg (as hyclate)</p>	<p>Premier choix</p> <p><i>Chlamydia trachomatis</i></p> <p><i>Cholera</i></p> <p>Second choix</p> <p><i>Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)</i></p> <p><i>Chronic obstructive pulmonary disease with acute exacerbation</i></p> <p><i>Cholera [children]</i></p> <p>Autres indications</p> <p><i>Bacterial infection of unspecified site</i></p>

Eravacycline

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 50 mg lyophilized powder for injection</p>	Carbapenem resistant <i>Enterobacteriales</i>

Erythromycin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)</p> <p>Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)</p> <p>Oral > Solid: 250 mg (as stearate or ethylsuccinate)</p>	<p>Second choix</p> <p>Therapeutic equivalent to clarithromycin pour</p> <p>Acute pharyngitis</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Ethambutol

Section	Indications
<p>Antituberculosis medicines</p> <p>Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL</p> <p>Oral > Solid > dispersible tablet: 100 mg</p> <p>Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)</p>	<p>Other specified tuberculosis</p> <p>Tuberculosis</p>

Ethambutol + isoniazid

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 400 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethambutol + isoniazid + rifampicin

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 275 mg + 75 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethionamide

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid > dispersible tablet: 125 mg</p> <p>Oral > Solid > tablet: 250 mg</p>	<p>Multi-drug resistant Mycobacterium tuberculosis</p> <p>Tuberculous meningitis</p>

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Flomoxef

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection	Other specified other antibiotic resistant Enterobacteriales

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

Gatifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Gentamicin

Section	Indications
Access group antibiotics	Premier choix
Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	<p>Neonatal meningitis co-prescrite avec amoxicilline</p> <p>Sepsis without septic shock co-prescrite avec amoxicilline</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicilline</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicilline</p> <p>Sepsis without septic shock co-prescrite avec ampicilline</p> <p>Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicilline</p> <p>Peritoneal abscess (severe) co-prescrite avec ampicilline</p> <p>Peritonitis (mild-moderate) co-prescrite avec ampicilline</p> <p>Peritonitis (severe) co-prescrite avec ampicilline</p> <p>Peritoneal abscess (mild-moderate) co-prescrite avec benzylpenicilline</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicilline</p> <p>Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicilline</p> <p>Sepsis without septic shock co-prescrite avec benzylpenicilline</p>
	Second choix
	<p>Other specified prophylactic measures</p> <p>Gonococcal infection</p>
	Autres indications
	<p>Bacterial infection of unspecified site</p>

Imipenem + cilastatin

Section	Indications
Watch group antibiotics	<p>Second choix</p> <p>Therapeutic equivalent to meropenem pour</p> <ul style="list-style-type: none">Neutropenia (high-risk)
Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	<p>Therapeutic equivalent to meropenem pour</p> <ul style="list-style-type: none">Peritoneal abscess (severe)
	<p>Therapeutic equivalent to meropenem pour</p> <ul style="list-style-type: none">Peritonitis (severe)
Antituberculosis medicines	<p>Autres indications</p> <ul style="list-style-type: none">Pseudomonas aeruginosa resistant to other antibioticAntibiotic resistant Acinetobacter baumannii <p>Therapeutic equivalent to meropenem pour</p> <ul style="list-style-type: none">Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics	<ul style="list-style-type: none">Other specified other antibiotic resistant EnterobacterialesCarbapenem resistant EnterobacterialesCarbapenem-resistant Pseudomonas aeruginosa
Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection	

Isoniazid

Section	Indications
Antituberculosis medicines	<ul style="list-style-type: none">Other specified tuberculosisTuberculosis
Parenteral > General injections > IV: 100 mg per mL	
Oral > Solid > dispersible tablet: 100 mg	
Oral > Solid > tablet: 100 mg; 300 mg	

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines	<ul style="list-style-type: none">Tuberculosis
Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg	

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid > dispersible tablet: 50 mg + 75 mg	
Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg	

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines	Latent tuberculosis
Oral > Solid: 300 mg + 300 mg tablet (scored)	

Kanamycin (injection)

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Parenteral > General injections > IV: 1000 mg powder for injection (vial)	

Levofloxacin

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid > dispersible tablet: 100 mg	
Oral > Solid > tablet: 250 mg; 500 mg; 750 mg	

Linezolid

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases
Parenteral > General injections > IV: 2 mg per mL in 300 mL bag	Methicillin resistant Staphylococcus aureus
Oral > Liquid: 100 mg per 5 mL powder for oral liquid	Vancomycin resistant Staphylococcus aureus
Oral > Solid: 400 mg tablet; 600 mg tablet	Vancomycin resistant Enterococcus
Oral > Solid > dispersible tablet: 150 mg	
Oral > Solid > tablet: 600 mg	
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid > dispersible tablet: 150 mg	
Oral > Solid > tablet: 600 mg	

Meropenem

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Second choix Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
Antituberculosis medicines Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant Mycobacterium tuberculosis

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacteriales Carbapenem resistant Acinetobacter baumannii

Metronidazole

Section	Indications
Access group antibiotics	
Oral > Liquid: 200 mg per 5 mL (as benzoate)	Premier choix
Oral > Solid: 200 to 500 mg tablet	Intestinal infections due to <i>Clostridioides difficile</i>
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection	Trichomoniasis
Local > Rectal > Suppository: 500 mg; 1 g	co-prescrite avec cefazolin
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial	Other specified prophylactic measures
Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg	co-prescrite avec cefotaxime
	Peritonitis (severe)
	co-prescrite avec cefotaxime
	Peritonitis (mild-moderate)
	co-prescrite avec cefotaxime
	Peritoneal abscess (mild-moderate)
	co-prescrite avec cefotaxime
	Peritoneal abscess (severe)
	co-prescrite avec ceftriaxone
	Necrotising fasciitis
	co-prescrite avec ceftriaxone
	Peritonitis (severe)
	co-prescrite avec ceftriaxone
	Peritoneal abscess (mild-moderate)
	co-prescrite avec ceftriaxone
	Peritoneal abscess (severe)
	co-prescrite avec ceftriaxone
	Peritonitis (mild-moderate)
	Second choix
	co-prescrite avec ciprofloxacin
	Peritonitis (mild-moderate)
	co-prescrite avec ciprofloxacin
	Peritoneal abscess (mild-moderate)
	Autres indications
	Bacterial infection of unspecified site

Moxifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 100 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>
Oral > Solid > tablet: 400 mg	Tuberculosis

Nitrofurantoin

Section	Indications
Access group antibiotics Oral > Liquid: 25 mg per 5 mL oral liquid Oral > Solid > dosage form: 100 mg; 50 mg	Premier choix Infectious cystitis

Ofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Omadacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 100 mg lyophilized powder for injection Oral > Solid: 300 mg	Methicillin resistant <i>Staphylococcus aureus</i>

Oxazolidinones

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

Phenoxymethylpenicillin

Section	Indications
Access group antibiotics Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid Oral > Solid: 250 mg (as potassium salt) tablet Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)	Premier choix Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
	Autres indications
	Bacterial infection of unspecified site

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	Premier choix Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (high-risk) Peritonitis (severe) co-prescrite avec clindamycin Necrotising fasciitis

Plazomicin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500 mg per 10 mL	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacteriales

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem resistant <i>Acinetobacter baumannii</i> Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i>

Polymyxins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Pretomanid

Section	Indications
Antituberculosis medicines Oral > Solid > tablet: 200 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Procaine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	Premier choix <i>Congenital syphilis [children]</i> Second choix <i>Syphilis</i>

Protonamide

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to <i>ethionamide</i> pour Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Pyrazinamide

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 150 mg Oral > Solid > tablet: 400 mg; 500 mg	Tuberculosis

Rifabutin

Section	Indications
Antituberculosis medicines Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Liquid: 20 mg per mL	Other specified tuberculosis
Oral > Solid: 150 mg; 300 mg	
Parenteral > General injections > IV: 600 mg in vial powder for injection	
Antileprosy medicines	Leprosy
Oral > Liquid: 20 mg per mL	
Oral > Solid: 150 mg; 300 mg	

Rifapentine

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid > tablet: 150 mg; 300 mg	Latent tuberculosis

Spectinomycin

Section	Indications
Access group antibiotics	Second choix
Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Gonococcal infection
	Autres indications
	Bacterial infection of unspecified site

Streptomycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Sulfamethoxazole + trimethoprim

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule</p> <p>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid</p> <p>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet</p> <p>Oral > Solid > dispersible tablet: 100 mg + 20 mg</p>	<p>Premier choix</p> <p>Infectious cystitis</p> <p>Second choix</p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Tedizolid

Section	Indications
<p>Reserve group antibiotics</p>	<p>Therapeutic equivalent to linezolid pour</p> <p>Methicillin resistant Staphylococcus aureus</p> <p>Therapeutic equivalent to linezolid pour</p> <p>Vancomycin resistant Staphylococcus aureus</p> <p>Therapeutic equivalent to linezolid pour</p> <p>Vancomycin resistant Enterococcus</p>

Terizidone

Section	Indications
<p>Antituberculosis medicines</p>	<p>Therapeutic equivalent to cycloserine pour</p> <p>Multi-drug resistant Mycobacterium tuberculosis</p>

Tetracycline

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Solid: 250 mg (hydrochloride)</p>	<p>Bacterial infection of unspecified site</p>

Tigecycline

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 50 mg in vial powder for injection</p>	<p>Other specified bacterial diseases</p>

Trimethoprim

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 50 mg per mL</p> <p>Oral > Solid: 100 mg; 200 mg</p>	<p>Premier choix</p> <p>Infectious cystitis</p>

Vancomycin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection</p> <p>Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)</p> <p>Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection</p> <p>Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection</p>	<p>Premier choix</p> <p>Necrotising fasciitis</p> <p>co-prescrite avec ceftazidime</p> <p>Endophthalmitis</p> <p>co-prescrite avec ceftriaxone</p> <p>Endophthalmitis</p> <p>Second choix</p> <p>Neutropenia (high-risk)</p> <p>Intestinal infections due to Clostridioides difficile</p> <p>Autres indications</p> <p>Methicillin resistant Staphylococcus aureus</p>